Adagene (ADAG) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Adagene (ADAG) has outperformed NovaBridge Biosciences (NBP) over the past year, gaining 17.0% versus a loss of 78.2%. Over five years, ADAG leads with a -82.6% price change compared with -98.1% for NBP. NovaBridge Biosciences is the larger company by market cap ($146.2 million vs $138.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | NBP |
|---|---|---|
| Share price | $2.06 | $1.26 |
| Market cap | $138.32M | $146.16M |
| 1-day change | -14.17% | -2.33% |
| YTD return | +8.99% | -68.34% |
| 1-year return | +17.05% | -78.16% |
| 5-year return | -82.60% | -98.13% |
| EPS (TTM) | $-0.38 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | $-46.27M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $5.97 |
| 52-week low | $1.30 | $1.26 |
| Distance from 52-week high | -57.53% | -78.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.07% | +614.29% |
| Average volume | 286.63K | 390.05K |
| Shares outstanding | 67.14M | 116.00M |
| Employees | 128 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed NBP by 95.2 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
ADAG vs NBP FAQ
Which is bigger, Adagene or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $146.16M compared with $138.32M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or NBP?
ADAG returned +17.05% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.